Pre-operative Risk Factors and Clinical Outcomes Associated with Vasoplegia in Recipients of Orthotopic Heart Transplantation in the Contemporary Era.
Writer and Curator: Larry H. Bernstein, MD, FCAP
and
Curator: Aviva Lev-Ari, PhD, RN
- associated with high mortality and morbidity.
- low systemic vascular resistance ( SVR index <1,600 dyn∙seg/cm5/m2 ) and
- high cardiac output ( cardiac index >2.5 l/min/m2 )
- within the first 4 postoperative hours.
Methylene blue and vasoplegia: who, when, and how?
- dysregulation of endothelial homeostasis and subsequent endothelial dysfunction
- secondary to direct and indirect effects of multiple inflammatory mediators.
- an inhibitor of nitric oxide synthase (NOS) and guanylate cyclase (GC),
- the refractory hypotension associated with endothelial dysfunction of VS.
- persistent low systemic vascular resistance,
- despite multiple intravenous pressor drugs at high dose,
- between 6 and 48 hours after surgery.
- a higher body surface area (1.8 ± 0.25 vs 1.63 ± 0.36, p = 0.0007),
- greater history of thyroid disease (38.2% vs 18.5%, p = 0.0075) and
- a higher rate of previous cardiothoracic surgery (79% vs 48%, p = 0.0006).
- they were more frequently treated with aspirin (73% vs 48%, p = 0.005) and
- mechanical assist devices (ventricular assist devices [VADs]: 45% vs 17%, p < 0.0001;
- total artificial hearts: 8.6% vs 0%, p < 0.0001), and
- less treated with milrinone (14.7% vs 45.8%, p = 0.0005).
- higher mortality (3.2% vs 17.1%, p = 0.0003) and morbidity in the first 30 days after transplant.
- were independent risk factors for development of vasoplegia syndrome.
- High body mass index,
- long cardiopulmonary bypass time,
- prior cardiothoracic surgery,
- mechanical support,
- use of aspirin, and
- thyroid disease
Related articles
- Decreased postoperative atrial fibrillation following cardiac transplantation (pharmaceuticalintelligence.com)
- 6-Year-Old Catonsville Girl Fights For Her Life After Heart Transplant (baltimore.cbslocal.com)
- One Year Later, Heart Transplant Recipient Doing Well (foxct.com)
- Girl on ventilator after lung transplants (cnn.com)
- Heart Failure Treatment Improves, But Death Rate Remains High : NPR (pharmaceuticalintelligence.com)
- Heart transplantation research in the next decade – a goal to achieving evidence-based outcomes (pharmaceuticalintelligence.com)
- Beta-Blocker Response (23andme.com)
- First drug to improve heart failure mortality in over a decade – HealthCanal.com (pharmaceuticalintelligence.com)
- Advanced heart failure (pharmaceuticalintelligence.com)
- Scientists prevent heart failure in mice (pharmaceuticalintelligence.com)
Other related articles fpublished on thie Open Access Online Sceintific Journal include the following:
Phrenic Nerve Stimulation in Patients with Cheyne-Stokes Respiration and Congestive Heart Failure (larryhbern)
http://pharmaceuticalintelligence.com/2013/06/20/phrenic-nerve-stimulation-in-patients-with-cheyne-stokes-respiration-and-congestive-heart-failure/
First drug to improve heart failure mortality in over a decade – HealthCanal.com (Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2013/06/03/first-drug-to-improve-heart-failure-mortality-in-over-a-decade-healthcanal-com/
Meta-analysis: Heart Failure Worsens Short-term Prognosis of NSTE-ACS Patients – TCTMD
(Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2013/06/06/meta-analysis-heart-failure-worsens-short-term-prognosis-of-nste-acs-patients-tctmd/
Scientists prevent heart failure in mice (Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2013/05/29/scientists-prevent-heart-failure-in-mice/
Economic Toll of Heart Failure in the US: Forecasting the Impact of Heart Failure in the United States – A Policy Statement From the American Heart Association (Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2013/04/25/economic-toll-of-heart-failure-in-the-us-forecasting-the-impact-of-heart-failure-in-the-united-states-a-policy-statement-from-the-american-heart-association/
Stenosis, ischemia and heart failure (Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2013/05/16/stenosis-ischemia-and-heart-failure/
Congestive Heart Failure & Personalized Medicine: Two-gene Test predicts response to Beta Blocker Bucindolol (Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2012/10/17/chronic-heart-failure-personalized-medicine-two-gene-test-predicts-response-to-beta-blocker-bucindolol/
Gene Therapy Into Healthy Heart Muscle: Reprogramming Scar Tissue In Damaged Hearts
(Aviva Lev-Ari)
Heart Renewal by pre-existing Cardiomyocytes: Source of New Heart Cell Growth Discovered
Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2012/12/23/heart-renewal-by-pre-existing-cardiomyocytes-source-of-new-heart-cell-growth-discovered/
Heart Remodeling by Design – Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony (Aviva lev-Ari)
Survivals Comparison of Coronary Artery Bypass Graft (CABG) and Percutaneous Coronary Intervention (PCI) / Coronary Angioplasty (larryhbern)
http://pharmaceuticalintelligence.com/2013/06/23/comparison-of-cardiothoracic-bypass-and-percutaneous-interventional-catheterization-survivals/
First case in the US: Valve-in-Valve (Aortic and Mitral) Replacements with Transapical Transcatheter Implants – The Use of Transfemoral Devices (larryhbern)
http://pharmaceuticalintelligence.com/2013/06/23/valve-in-valve-replacements-with-transapical-transcatheter-implants/
Ventricular Assist Device (VAD): A Recommended Approach to the Treatment of Intractable Cardiogenic Shock (larryhbern)
http://pharmaceuticalintelligence.com/2013/06/18/a-recommended-approach-to-the-treatmnt-of-intractable-cardiogenic-shock/
Trans-apical Transcatheter Aortic Valve Replacement in a Patient with Severe and Complex Left Main Coronary Artery Disease (LMCAD) (larryhbern)
http://pharmaceuticalintelligence.com/2013/06/17/management-of-difficult-trans-apical-transcatheter-aortic-valve-replacement-in-a-patient-with-severe-and-complex-arterial-disease/
Clinical Indications for Use of Inhaled Nitric Oxide (iNO) in the Adult Patient Market: Clinical Outcomes after Use, Therapy Demand and Cost of Care (Aviva Lev-Ari)
http://pharmaceuticalintelligence.com/2013/06/03/clinical-indications-for-use-of-inhaled-nitric-oxide-ino-in-the-adult-patient-market-clinical-outcomes-after-use-therapy-demand-and-cost-of-care/

Space-filling model of the cyclic guanosine monophosphate molecule, also known as cGMP, a nucleotide. This image shows the anionic (negatively charged) form. Colour code (click to show) : Black: Carbon, C : White: Hydrogen, H : Red: Oxygen, O : Blue: Nitrogen, N : Orange: Phosphorus, P (Photo credit: Wikipedia)

Ball-and-stick model of the cyclic guanosine monophosphate molecule, also known as cGMP, a nucleotide. This image shows the anionic (negatively charged) form. Colour code (click to show) : Black: Carbon, C : White: Hydrogen, H : Red: Oxygen, O : Blue: Nitrogen, N : Orange: Phosphorus, P (Photo credit: Wikipedia)
Leave a Reply